Transcranial magnetic stimulation has matured into one of the most clinically established interventional treatments for depression and increasingly for other psychiatric indications. The 2026 landscape includes standard left-DLPFC protocols, the briefer theta-burst stimulation (FDA-approved 2018), and the accelerated SAINT-style protocols (FDA-cleared 2022) that compress treatment into 5 days. Effect sizes in TRD are meaningful — response rates of 50–60% and remission rates of 30–40% in standard treatment — with the substantial advantage over ECT of no anesthesia, no cognitive impairment, and in many cases cognitive enhancement during treatment.
The standard protocol is daily left dorsolateral prefrontal cortex stimulation at 10 Hz for 6 weeks (30 sessions). Each session is 30–40 minutes. The mechanism involves induction of long-term potentiation in the targeted circuit; downstream effects include modulation of subgenual cingulate, amygdala, and broader mood-regulating networks. Side effects are limited — scalp discomfort, headache, rare seizure risk (~1 in 30,000 treatments). The access pattern requires daily clinic attendance for 6 weeks; this is the limiting factor for many patients.
Theta-burst stimulation compresses the session. Intermittent theta-burst stimulation (iTBS) delivers the equivalent of a standard TMS session in 3 minutes, allowing more practical clinic flow. Efficacy in head-to-head trials has been comparable to standard protocols. The clinical utility is substantial — patient adherence improves, throughput improves, the practical barriers to completing a full course reduce. Most current TMS clinics offer theta-burst as their primary protocol.
Accelerated protocols (SAINT) deliver substantially compressed treatment. The Stanford SAINT protocol uses 10 sessions daily for 5 consecutive days at higher-than-standard intensity with functional MRI targeting; the original trial showed remarkable response rates. The FDA cleared accelerated theta-burst (1Hz stim, modified protocols) in 2022; multiple commercial accelerated programs are available. The clinical advantage is dramatic compression of the treatment course — 5 days versus 6 weeks. Cost and access remain limitations; insurance coverage varies; functional MRI targeting is not universally available.
The cognitive-protective profile is the longevity-psychiatry advantage. TMS produces no anesthesia exposure (unlike ECT), no cognitive impairment as a side effect (also unlike ECT), and in some trials produces cognitive enhancement during treatment particularly in executive function domains. For patients where cognitive preservation matters — older adults, patients with cognitive concerns, patients in cognitively-demanding work — TMS is the interventional option that does not carry the cognitive cost of alternatives.
The clinical decision points. TMS is appropriate for TRD when adequate medication trials and psychotherapy have produced inadequate response. The choice between TMS, ECT, and ketamine depends on severity, urgency, prior treatment response, cognitive considerations, and access. ECT remains more effective for the most severe presentations (melancholic features, psychotic features, catatonia); TMS is generally preferred when cognitive considerations matter and severity allows. Newer applications — OCD (FDA-approved 2018), nicotine dependence (FDA-approved 2020), bipolar depression (off-label, emerging evidence), PTSD (off-label, emerging evidence) — extend the clinical footprint. The discipline is to consider TMS earlier in the TRD pathway than has historically occurred, recognize its cognitive-protective profile in patients where this matters, and choose the protocol variant that matches patient access and clinical need.